TICKERNERD
Menu
MPLTMPLTHealthcare · Biotechnology

MPLT Stock Forecast: MapLight Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$13
−3.61% on the day

The 14 Wall Street analysts covering MapLight Therapeutics, Inc. hold a median 12-month price target of $30 — +139.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 5 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$590.4M
Ticker Nerd rank
5 / 100
Median analyst target
$30
Analysts covering
14
Total return, dividends reinvested
1W
+26.7%
1M
−66.2%
YTD
−28.6%
From high
−68.5%
From low
+26.7%
$10
$40
Range since 27 Oct 2025, adjusted closes · the dot is the last close
Ticker Nerd rank

MPLT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MapLight Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
5 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
51
Accruals
38
Issuance
35
Revisions
26
Value
26
Quality
23
Growth
8
Momentum
3
Volatility
3

Size (51): Smaller than most of the companies we track.

Volatility (3): The share price moves around a lot.

The rank is the raw material. Whether the rules would actually own MapLight Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

MPLT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MPLT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 27 Oct 2025Adjusted close, US dollars
$10$20$30$40$50Jan 26Apr 26Jul 26MPLTHigh $52Median $30Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says14 analysts
13 Buy1 Hold0 Sell
Low $20Median $30High $52

The green dot is the last close — the median target sits +139.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
28 July 2026Canaccord GenuityMaintainsBuy$43 → $24
28 July 2026HC Wainwright & Co.MaintainsBuy$45 → $26
28 July 2026Morgan StanleyDowngradeEqual-Weight$34 → $21
25 July 2026Canaccord GenuityMaintainsBuy—
24 July 2026Canaccord GenuityMaintainsBuy$35 → $43
21 July 2026BMO CapitalInitiatesOutperform$46
21 July 2026BMO CapitalInitiatesOutperform—
21 July 2026UBSMaintainsBuy$48 → $52
21 July 2026UBSMaintainsBuy—
10 July 2026NeedhamMaintainsBuy—
10 July 2026NeedhamMaintainsBuy$42 → $45
25 June 2026Raymond JamesInitiatesStrong Buy—
23 June 2026Craig-HallumMaintainsBuy—
22 June 2026NeedhamMaintainsBuy—
2 June 2026StifelMaintainsBuy—
28 May 2026HC Wainwright & Co.ReiteratesBuy—
27 May 2026UBSInitiatesBuy—
21 May 2026Craig-HallumInitiatesBuy—
4 May 2026HC Wainwright & Co.InitiatesBuy—
8 Apr 2026NeedhamInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

MPLT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

MapLight Therapeutics, Inc. (MPLT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.7×

Cheaper than 80% of US stocks

Price / sales
—
Price / book
1.5×

Cheaper than 56% of US stocks

EV / EBITDA
−1.4×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−81.0%

Higher than 15% of US stocks

Return on assets
−49.5%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MPLT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MPLTMapLight Therapeutics, Inc.$590.4M
5
ZVRAZevra Therapeutics, Inc.$558.3M
99
RLMDRelmada Therapeutics, Inc.$557.0M
53
ALTAltimmune, Inc.$552.0M
30
CRMDCorMedix, Inc.$589.9M
65
IMMXImmix Biopharma, Inc.$592.3M
44
CTNMContineum Therapeutics, Inc.$600.3M
66
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MPLT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest MPLT news & analysis

MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law

PRNewsWire · 3 Aug 2026negative

Shareholder rights law firm Schall, Brown & Schwartz LLP announced it is investigating claims on behalf of MapLight Therapeutics investors for possible violations of securities laws. The investigation focuses on whether MapLight issued false and/or misleading statements or failed to disclose information pertinent to investors.

Why it matters — An active securities-law investigation raises legal and reputational risk that MPLT investors would want to monitor in the company's news.

MapLight Therapeutics, Inc. (MPLT) Discusses Top Line Results of Phase 2 ZEPHYR Study of ML-007C-MA in Schizophrenia Transcript

Seeking Alpha · 28 July 2026neutral

MapLight Therapeutics discussed the top line results of its Phase 2 ZEPHYR study of ML-007C-MA, a treatment for schizophrenia, in a transcript published by Seeking Alpha.

Why it matters — MPLT watchers would care because the Phase 2 ZEPHYR results are a key milestone for the company's lead pipeline candidate, ML-007C-MA, and could signal the drug's potential trajectory toward regulatory advancement.

Maplight Therapeutics' Schizophrenia Drug Hits Phase II Primary Endpoint

MarketBeat · 27 July 2026positive

Maplight Therapeutics reported that its Phase II ZEPHYR trial of ML-007C-MA met its primary endpoint in schizophrenia, with the twice-daily regimen showing a statistically significant improvement in PANSS total scores versus placebo at five weeks.

Why it matters — A positive Phase II readout moves ML-007C-MA closer to potential regulatory filing and reinforces MPLT's position in schizophrenia treatment.

MapLight Therapeutics Stock Falls Despite Schizophrenia Drug Meeting Main Trial Goal

Benzinga · 27 July 2026negative

MapLight Therapeutics reported positive topline data from its Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia, yet its stock still fell on Monday.

Why it matters — The stock decline despite a successful trial outcome suggests that investor expectations may have differed from the trial results or that other market factors influenced the price.

FAQ

Frequently asked questions about MPLT stock

What is the MPLT stock price forecast for 2026-2027?

The 14 Wall Street analysts covering MapLight Therapeutics, Inc. have a median 12-month price target of $30, with estimates ranging from $20 to $52. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MPLT stock a buy right now?

Of the 14 analysts covering MapLight Therapeutics, Inc., 13 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MapLight Therapeutics, Inc. 5 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MPLT?

As at 1 Aug 2026, MapLight Therapeutics, Inc. ranks 5 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (51 of 100).

Will MPLT stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +139.0% from the last close, and Ticker Nerd's factor model ranks MapLight Therapeutics, Inc. 5 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MPLT stock forecast for 2030?

No analyst covering MapLight Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MPLT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $52 over the next 12 months.

What does MapLight Therapeutics, Inc. do?

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for central nervous system (CNS) disorders.

What is the latest news on MPLT?

The most recent item we track (PRNewsWire, 3 Aug 2026): "MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law". Shareholder rights law firm Schall, Brown & Schwartz LLP announced it is investigating claims on behalf of MapLight Therapeutics investors for possible violations of securities laws. The investigation focuses on whether MapLight issued false and/or misleading statements or failed to disclose information pertinent to investors.

Company

About MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for central nervous system (CNS) disorders. Its primary focus is on discovering and advancing circuit-specific treatments designed to address severe and difficult-to-treat brain conditions such as schizophrenia, Alzheimer’s disease psychosis, autism spectrum disorder, and Parkinson’s disease. The company's leading drug candidate, ML-007C-MA, combines M1/M4 muscarinic agonism with a peripherally acting anticholinergic, specifically targeting symptoms of schizophrenia and Alzheimer’s disease-related psychosis. Additional candidates in the pipeline address social deficits in autism, motor issues in Parkinson’s disease, and agitation-related disorders through novel pharmacological approaches. Founded in 2018 by leaders in psychiatry and neuroscience, MapLight Therapeutics leverages a proprietary discovery platform that identifies and modulates neural circuits causally linked to disease, aiming to move beyond the limitations of traditional CNS medications. The company plays a significant role in the ongoing evolution of neuropsychiatric drug development, prioritizing scientific rigor and circuit specificity to potentially offer safer and more effective therapeutic options for underserved patient populations.

CEO Dr. Christopher A. Kroeger M.B.A., M.D., Ph.D. · 133 employees · United States · https://www.maplightrx.com